# A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Source: https://onco.cc/trials/nct05754853/  
OnCo record `nct05754853` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing MRG002 in bladder & urothelial cancer, now recruiting.

## Summary

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT05754853, led by Shanghai Miracogen, and recruiting on the registry. Official title: An Open-label, Randomised, Multi-centre, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors. Planned enrolment is 290 participants (estimated). The study started in 2023-04-06 and primary completion is expected in 2025-10. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05754853
- Phase: 3
- Setting: An Open-label, Randomized, Multi-center, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors
- Sponsor: Shanghai Miracogen
- Enrolled: 290

## Sources

- ClinicalTrials.gov NCT05754853: https://clinicaltrials.gov/study/NCT05754853

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Muscle-invasive and advanced bladder cancer](https://onco.cc/cancers/muscle-invasive-bladder-cancer/)
- drugs: [MRG002](https://onco.cc/drugs/mrg002/)
- companies: [Shanghai Miracogen](https://onco.cc/companies/shanghai-miracogen/)

---
JSON: https://onco.cc/api/v1/entities/nct05754853.json